Navigation Links
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
Date:1/9/2009

BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-day study of hepatitis C virus (HCV) protease inhibitor ITMN-191 (R7227) in combination with Pegasys(R) (interferon alfa-2a) and Copegus(R) (ribavirin) in patients chronically infected with HCV genotype 1. ITMN-191 is being developed in collaboration with Roche.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 80676348. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80676348.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
4. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
10. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
11. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... 7, 2007 - REGENERX,BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com ... the 2007 Association for Research in,Vision and ... May 9th to discuss TB4's ability to ... process closely,associated with inflammation that, if not ...
... TSX-V: PGA, VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - ... results from its Phase I/II study of PAC-113, ... and active,in the treatment of oral Candida infection ... of care. Based on these results,the Company plans ...
Cached Medicine Technology:Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 2Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 2Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 4Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 5
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Colorado (PRWEB) January 22, 2015 Four years since ... Queen – which coincided with the marriage of Avasa & Matthew ... THE ROAD, which is scheduled for release through White Swan Records ... message that there is a sacred path available to all of ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance ... reducing the costs of an auto insurance policy . , ... lower prices for their vehicle insurance policies. The safety a vehicle ... costs. Because of this, drivers should always carry a first ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , WEDNESDAY, Nov. 3 (HealthDay News) -- Friendly ... challenges, but conversations that are competitive in tone aren,t helpful, ... talking to other people, the way you do when you,re ... a psychologist and researcher at the Institute for Social Research ...
... are less healthy than their English counterparts, but they live as ... new study by researchers from the RAND Corporation and the Institute ... aged 55 to 64 have higher rates of chronic diseases ... rate. And Americans age 65 and older -- while still sicker ...
... Mitchell, M.D., clinical professor, Department of Medical Oncology ... and associate director of Diversity Programs for the ... ,Physician of the Year, by CancerCare, a national ... to anyone affected by cancer: people with cancer, ...
... WEDNESDAY, Nov. 3 (HealthDay News) -- Higher levels of ... for Medicare patients, a new study has found. ... Information Set revealed wide variation across the United States ... inappropriate prescriptions for the elderly, said the researchers at ...
... Film director Ken Loach has officially opened a new ... between parents and children with hearing difficulties. The ... Health Research (NIHR) Biomedical Research Unit in Hearing, a ... Trust and the Medical Research Council Institute for Hearing ...
... the Cincinnati Veterans Affairs (VA) Medical Center have found that ... therapies for high blood pressure do not often adhere to ... online edition of the American Journal of Nephrology . ... Cincinnati VA, showed that treatment of hypertension in patients with ...
Cached Medicine News:Health News:Good Conversation Can Boost Brain Power, Study Finds 2Health News:Americans less healthy than English, but live as long or longer, study finds 2Health News:Americans less healthy than English, but live as long or longer, study finds 3Health News:CancerCare names Jefferson professor Physician of the Year 2Health News:Pricey Drugs May Not Mean Better Care 2Health News:Film director launches pioneering hearing research 2Health News:Medication adherence improves blood pressure control in chronic kidney disease 2
... at the palmar crease to allow for full ... to treat mild to moderate wrist sprains and ... cast removal. The lightweight laminated foam glove ... support and compression to the wrist to help ...
... is an excellent choice to treat DeQuervain's ... joint, basal joint arthritis, advanced carpal tunnel ... thumb and wrist. Distal palmar crease ... and full finger dexterity. Constructed from ...
... solid, one-piece custom wrist orthotic designed to keep the ... ,Indications: , Wrist reconstruction , Wrist ... Coles fracture - distal radius , Scaphoid ... ORIF - Open reduction and internal fixation for ...
... wrist orthotic designed to limit the extension of the ... ,Indications: , Wrist reconstruction , Wrist ... Coles fracture - distal radius , Scaphoid ... ORIF - Open reduction and internal fixation for ...
Medicine Products: